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A B S T R A C T
Inhaled airway challenges provoke bronchoconstriction in susceptible subjects and are a pivotal tool in the
diagnosis and monitoring of obstructive lung diseases, both in the clinic and in the development of new re-
spiratory medicines. This article reviews the main challenge agents that are in use today (methacholine, man-
nitol, adenosine, allergens, endotoxin) and emphasises the importance of controlling how these agents are ad-
ministered. There is a danger that the optimal value of these challenge agents may not be realised due to
suboptimal inhaled delivery; thus considerations for eﬀective and reproducible challenge delivery are provided.
This article seeks to increase awareness of the importance of precise delivery of inhaled agents used to challenge
the airways for diagnosis and research, and is intended as a stepping stone towards much-needed standardisation
and harmonisation in the administration of inhaled airway challenge agents.
1. Introduction
Inhaled airway challenges are a key tool in the study and diagnosis
of obstructive lung diseases. Bronchial challenge tests that measure
bronchial hyperresponsiveness (BHR) of the airways have established
applications in the clinic, where they are used to rule out or conﬁrm a
diagnosis of asthma [1,2]. Inhaled airway challenges can also be used to
study disease mechanisms and symptoms other than BHR, either by
varying the outcome measure (e.g. inﬂammation measured by exhaled
nitric oxide or inﬂammatory cell count) or the stimulus (e.g. allergen or
endotoxin). The various airway challenges thereby allow the mon-
itoring of disease activity and eﬀectiveness of treatments [3], and they
can provide a robust disease model in early phase clinical trials [4,5].
Given the reliance on inhaled airway challenges in respiratory medi-
cine, there is surprisingly little standardisation of techniques or gui-
dance regarding the administration of diﬀerent test agents. In this ar-
ticle we consider various challenge agents and discuss the importance
of standardisation and harmonisation of their administration methods.
Historically, bronchial challenge tests have been developed to
measure BHR by means of spirometry and the change in forced ex-
piratory volume in 1 s (FEV1) is still considered the primary outcome
measure in the recently published technical standard on methacholine
challenge testing [6]. However, whether FEV1 is the most appropriate
outcome measure is subject of debate and a recent study points out that
the change in eﬀective speciﬁc airway conductance (sGeﬀ) measured
with body plethysmography actually has a much larger diagnostic value
than FEV1 for the challenge agent methacholine [7]. Other techniques
that can be used to measure airway function after provocation include
forced or impulse oscillometry (airway resistance) [8] and multiple
breath nitrogen washout (ventilation heterogeneity) [9]. The relative
value of these techniques in challenge testing is beyond the scope of this
paper. In this review we will refer to the outcome measure in a general
way in appreciation of this on-going discussion.
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2. Inhaled airway challenge agents
Bronchial challenge testing can be performed with a wide range of
stimuli, with selection of a particular agent depending on the aim of the
test. BHR can be measured using stimuli that have either a direct eﬀect
on airway smooth muscle (ASM) (e.g. methacholine or histamine) or an
indirect eﬀect where the inhaled agent stimulates inﬂammatory or
neuronal cells (e.g. mannitol, bradykinin or AMP) [10]. Furthermore,
certain agents can be used that trigger other (patho)physiological me-
chanisms in the airways (e.g. endotoxin-induced inﬂammation or al-
lergen-induced responses in allergic subjects), possibly accompanied by
BHR in susceptible subjects.
2.1. Direct challenge agents
The most commonly used stimulus in bronchial challenge testing is
the direct-acting stimulus methacholine, a synthetic analogue of the
neurotransmitter acetylcholine that acts as an agonist on muscarinic M3
receptors on ASM cells. Histamine, an agonist for the histamine H1
receptors on ASM cells, can also be used, although this compound is
associated with more systemic side eﬀects such as ﬂushing and head-
ache due to vasodilation [11]. When a direct-acting stimulus is used the
test generally has a high sensitivity for asthma, meaning that the ma-
jority of asthma patients will respond to this stimulus, and the re-
sponsiveness increases with the severity of lung disease [1]. However,
the speciﬁcity is poor since healthy subjects also respond when the dose
is high enough; they are just less sensitive and less reactive to the sti-
mulus than asthmatic subjects (Fig. 1). Even though cut-oﬀ values for
healthy and hyperresponsive individuals have been agreed upon
[1,6,11], these values can still be considered as quite arbitrary due to
the many factors aﬀecting lung deposition of the stimulus, such as the
patient's breathing pattern or the presence of emphysema, inﬂamma-
tion, mucus deposition and/or oedema. Moreover, it is becoming clear
that methacholine can miss newly diagnosed asthmatic subjects whose
symptoms are mild and whose lung function is excellent, but who de-
monstrate asthma in terms of signiﬁcant exercise-induced broncho-
constriction [12]. However, the use of a diﬀerent predeﬁned threshold
value for the outcome measure in methacholine challenge as compared
to exercise-induced bronchoconstriction (i.e., 20% reduction in FEV1 in
the former versus 10–15% reduction in FEV1 in the latter) may explain,
at least in part, such discrepancy. Additionally, testing with metha-
choline does not allow for absolute diﬀerentiation between patients
with asthma or COPD, or indeed other diseases such as allergic rhinitis
[13–16].
2.2. Indirect challenge agents
In the search for stimuli that produce responses through mechan-
isms that better reﬂect the underlying disease pathology, indirect
challenges have been introduced, which exert their eﬀects on inter-
mediary cells involved in the asthmatic response, rather than acting
directly on ASM. Most indirect stimuli evoke a heterogeneous response
by aﬀecting multiple pathophysiological pathways [3]. Especially in the
1980s and 1990s many diﬀerent potential indirect stimuli have been
investigated, which have been reviewed comprehensively by Van
Schoor et al., ﬁrst in 2000 [10], and subsequently updated in 2005 by
the same authors [17]. In 2003, a European Respiratory Society (ERS)
Task Force published their recommendations on the use of indirect
stimuli in diagnosis and monitoring of asthma [3].
Indirect stimuli can be sub-classiﬁed as physical or pharmacological
stimuli. Physical stimuli induce airways obstruction without acting on
speciﬁc receptors, exempliﬁed by exercise-induced bronchoconstriction
or that induced by “fog” challenges with distilled water or hypotonic
aerosols [18,19]. Exercise induces dehydration of the airway epithe-
lium, resulting in an increased osmolarity of the airway lumen and
subsequent release of mediators from mast cells and activation of sen-
sory nerves [20]. This process is mimicked during challenge with hy-
perosmolar aerosols [21,22]. Pharmacological stimuli induce airways
obstruction secondary to the activation of intermediary cell types, such
as inﬂammatory, epithelial, or neuronal cells, or combinations of these.
The eﬀects of indirect agents depend on the speciﬁc cells and receptors
involved [10], but many of the stimuli used are known to activate
sensory nerves, for example bradykinin, sulphur dioxide and adenosine
(reviewed in Ref. [23]). Some indirect stimuli are endogenous com-
pounds known to be released during airways obstruction, such as
adenosine, AMP, tachykinins and bradykinin [24–31]. Another group of
indirect-acting stimuli is comprised of sulphur-containing compounds,
which originated from the observation that sulphur dioxide, a common
air pollutant, and sulphites used as preservatives in food processing,
may induce bronchoconstriction in susceptible subjects through acti-
vation of sensory neuronal pathways [32,33]. However, lack of re-
producible test outcomes has led to discontinuation of studying several
of these stimuli (sulphur dioxide, sodium metabisulphite, bradykinin
and tachykinins) and focus has predominantly shifted to the most easily
and widely applicable indirect stimuli, mannitol (physical) and AMP/
adenosine (pharmacological).
2.3. Allergen challenge
The preceding “non-speciﬁc” bronchial challenge tests are targeted
to mechanisms that are thought to be intrinsic to the underlying hy-
perresponsive state of the airways in subjects with asthma. In contrast,
so-called “speciﬁc” airway challenges can be used to assess the airway
responsiveness to sensitising agents, such as aeroallergens or occupa-
tional agents. In allergic subjects, following sensitisation to an allergen,
minute quantities of that allergen are suﬃcient to cause an immediate
IgE-mediated early asthmatic response (EAR). In approximately 50% of
positive allergen challenges a recurrence of airﬂow obstruction occurs
between 3 and 8 h after allergen exposure, the so-called late asthmatic
response (LAR) [34], which is associated with airway inﬂammation and
in some patients can be associated with an increase in BHR to agents
like methacholine [35–37]. Often-used outcome measures for inhaled
allergen challenge are a>15% decrease in FEV1,> 50% decrease in
speciﬁc airway conductance, or> 100% increase in speciﬁc airway
resistance compared to baseline [38]. Additional outcome measures can
be the change in non-speciﬁc BHR to e.g. methacholine, or the occur-
rence of airway inﬂammation expressed as increase in sputum eosino-
phils or exhaled nitric oxide [38]. Inhaled allergen challenge has also
been widely used as a model to assess the eﬃcacy of novel therapeutic
interventions [39–49].
2.4. LPS challenge
Another interesting application of the inhaled airway challenge test
concept is provocation with lipopolysaccharide (LPS), also called
















Fig. 1. Dose-response curves to inhaled methacholine in a healthy, mild-asthmatic, and
severe-asthmatic subject, showing both the leftward shift of the curve (hypersensitivity)
and steeper slope (hyperreactivity) that characterise BHR. Reproduced with permission
from the European Respiratory Society [1,117].
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endotoxin, a major component of the outer membrane of Gram-nega-
tive bacteria that induces fever and inﬂammation upon systemic ex-
posure [50]. Aerosolised endotoxins are present ubiquitously in the
environment in concentrations that do not elicit immune responses.
However, in certain aerosols, like tobacco smoke and organic dusts,
concentrations can be high enough to induce responses in the lungs
[51]. Inhalation of endotoxin has been associated with lung in-
ﬂammation, most notably neutrophilia [52–54]. It can further lead to
bronchial obstruction in people with asthma or other forms of BHR
[55,56]. Interestingly, it has recently been reported that LPS can elicit
BHR through a mechanism involving cholinergic transmission [57].
Airway challenge with a nebulised LPS solution has been used
mainly to study neutrophilic inﬂammatory processes in the lungs and
has been developed into a challenge model to investigate the eﬀect of
novel anti-inﬂammatory drugs under development for the treatment of
diseases that are associated with neutrophil inﬁltration into the lungs,
particularly COPD and severe asthma, as this challenge is not sensitive
to treatment with glucocorticosteroids [5,58–61]. This model has also
been used for early proof-of-concept and dose-ranging studies for novel
drugs for the treatment of respiratory diseases in healthy volunteers
[58,62].
3. General considerations for challenge delivery to the lungs
Despite the wide array of challenge test agents, there are relatively
few methods used for their administration. Hence various aspects need
to be considered that apply to airway challenge methodology in gen-
eral, irrespective of the agent that is used.
3.1. Delivered dose
Inhaling a challenge agent usually leads to a dose-dependent re-
sponse in the lungs. For challenges that induce BHR, the minimal dose
required to obtain a response, as well as the slope of the dose-response
curve, varies amongst patients and deﬁnes the severity of their BHR [1].
The aim of such bronchial challenge tests is to induce a pre-deﬁned
degree of bronchoconstriction without risking a response that is too
severe, meaning that the dose of the stimulus requires titration. For this
reason, ascending dosing protocols have been developed in which the
stimulus is administered by nebulisation of ascending (usually dou-
bling) concentrations or doses, after each of which the lung function is
measured [1,6,11,63,64]. The concentration or dose is gradually in-
creased and the test continues until a predeﬁned threshold value for the
outcome measure is obtained. The test result is negative when the
threshold value is not reached after administration of the top dose.
This methodology has been initially developed for direct stimuli
[65], but indirect-acting stimuli are generally administered following
similar dosing protocols [3], although diﬀerent concentrations (or
doses) may be used to accommodate diﬀerences in potency, as shown in
Fig. 2. For AMP for example, a 16-fold lower potency has been reported
compared to methacholine [66]. Allergen exposure should be increased
gradually either by extending the duration of the exposure or increasing
the concentration in order to prevent severe acute reaction [38]. For the
same safety reason, allergen dose increments should have longer time
intervals (10–15min) compared to direct or indirect challenge methods
(< 5min). Due to their speciﬁc mode of action, as little as a few ng can
suﬃce to elicit the airway response. Endotoxin challenge on the other
hand is usually administered by nebulisation of a ﬁxed dose in the μg-
range.
It is clear that due to these diﬀerences in dosimetry, the various
challenges require diﬀerent methods for administration. However,
currently no universally standardised methodology is used in the ma-
jority of cases to deliver these diﬀerent agents. It is important to realise
that this may have important implications that are now largely ne-
glected by the ﬁeld.
3.2. Administration by nebulisation
Most challenge agents are administered by nebulisation, except for
mannitol and an investigational formulation of adenosine that are both
administered as a dry powder (see below). Preparing nebuliser for-
mulations can be very straightforward, which is the main reason why
nebulisers are often used for oﬀ-label or investigational drugs and non-
medicinal compounds, like many of the agents used for challenge
testing. However, it has to be carefully evaluated whether the for-
mulation aﬀects nebuliser performance (in terms of droplet size and
output rate) and, in the case of more complex molecules, whether the
nebulisation process leads to degradation of the agent (e.g. allergens of
biological origin).
Two standardised dosing protocols have been published for ad-
ministration of methacholine by nebulisation [6,11]. The two methods
have diﬀerent pros and cons, and the choice of method has been left to
the preference of individual investigators/clinicians. The dosimeter
method involves ﬁve deep and slow inhalations, which allows for ac-
curate quantiﬁcation of the administered dose, thereby making this
method suitable for studies that require administration of an exact dose,
such as LPS challenge studies or allergen challenges using a bolus dose.
It has been claimed, however, that such deep breaths have broncho-
protective and bronchodilatory eﬀects per se [67–69], which may
therefore interfere with an accurate interpretation of the test result. In
the newest technical standard on methacholine challenge testing a
deep-breath method is therefore not recommended [6]. The other
method is the tidal breathing method in which the stimulus is inhaled
during a speciﬁed time of calm, tidal breathing, although the patient's
inhalation ﬂow rate is generally not controlled. This more shallow way
of inhaling does not evoke bronchoprotective and bronchodilatory
mechanisms, but could result in diﬀerent deposition patterns of the
aerosolised challenge compared to the ﬁve-breath dosimeter method,
since penetration of the aerosol into the more distal airways is depen-
dent on the mixing of old and new air in the lungs. Moreover, the total
amount that is inhaled depends on the inspiratory cycle of the subject,
but also on the output rate of the nebuliser. In the ﬁrst universal
(American Thoracic Society) guidelines on methacholine challenge
testing, the output rate had therefore been standardised at 0.13mL/min
(based on the output rate of the Wright nebuliser that was commonly
used for challenge testing), regardless of the nebuliser that was used
[11]. However, adjusting the jet pressure to obtain this output rate may
have detrimental eﬀects on the droplet size distribution. As an example,
this has been shown for the SideStream nebuliser (Philips Respironics),
where the median mass aerodynamic diameter (MMAD) increased from
5.1 μm to 8.5 μm when the jet pressure was reduced from 1.5 bar
(manufacturer's speciﬁcations) to 0.5 bar to reach the required output
rate of 0.13mL/min [70]. To prevent such unforeseen changes, a better
strategy is to control the total administered volume of the solution








ng μg mg g 
Fig. 2. Dose ranges of various inhaled airway challenge agents. Allergens and LPS can
also be expressed in biological units and endotoxin units respectively.
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than using an output rate of the nebuliser outside of the manufacturer's
speciﬁcations, which is now discussed in the recently published Eur-
opean Respiratory Society technical standard on methacholine chal-
lenge testing [6].
In addition to the eﬀect of jet pressure on droplet size, the type of
compound and its concentration may aﬀect the droplet size distribution
as well. For AMP, which has a dose range exceeding that of metha-
choline, it has been shown that the increased viscosity of the more
concentrated solutions resulted in a large shift in the aerosol droplet
size distribution [70]. In this study, a decrease in MMAD of almost 50%
was measured at the highest AMP concentration (320mg/mL) com-
pared to saline and the lowest AMP concentrations. These results in-
dicate that applying methods developed for a certain stimulus and a
certain device cannot simply be used for other compounds or in other
situations without verifying their suitability.
A third factor that should be accounted for is the evaporation of
solvent (water) during nebulisation. The driving force for evaporation is
saturation of the outgoing air with solvent [71], which leads to an in-
crease in concentration of the remainder of the solution in the nebuliser
cup [70,72]. Importantly, evaporative water losses lead to an over-
estimation of the administered dose when the output rate is measured
gravimetrically [6]. Evaporation is an endothermic eﬀect and the en-
ergy needed for this process is drawn from the solution, resulting in a
temperature drop in the nebuliser solution that in turn may aﬀect the
output rate of the nebuliser [72]. Calibration of the nebuliser output
rate should therefore be performed under precise operating conditions.
Newer jet nebulisers and especially vibrating mesh nebulisers exhibit
much lower amounts of evaporative loss [6], but still it is preferable to
measure output rate by means of ﬁlter measurements (collection of the
active compound) rather than gravimetrically. Such data should either
be provided by the manufacturer or can be obtained in a pharmaceu-
tical lab specialised in inhaled drug delivery.
In contrast to methacholine, there are no universal standardised
protocols for other challenge agents, although recommendations have
been made for similar ascending administration protocols [3].
3.3. Aerosol deposition and distribution in the lungs
For optimal eﬃcacy and discriminatory power, inhaled medical
aerosols should achieve maximal delivery to, and deposition in the
target area in the lungs. Bronchial challenges that measure broncho-
constriction should be targeted to the proximal part of the bronchial
tree, where the eﬀects of ASM contraction are most pronounced. This
means that the requirements for aerosol particle size are quite easily
met, since an MMAD of roughly 3–5 μm should generally suﬃce,
especially at tidal breathing. Aerosols with particles in this size range
have the additional beneﬁt of increased deposition eﬃcacy, resulting in
a higher total lung dose compared to particles smaller than 1.5 μm [73].
It has indeed been found that aerosols with MMADs of 3 and 5 μm result
in a lower methacholine PC20 compared to those with an MMAD of
1 μm [74], which can be attributed to a combination of greater lung
deposited dose and targeting to the proximal airways.
It could be reasoned that challenges that act on inﬂammatory pro-
cesses should be targeted more distally, as inﬂammation occurs
throughout the lungs. However, investigations into the eﬀects of par-
ticle (droplet) size on airway responsiveness to AMP have thus far been
inconclusive due to a high number of non-responders to small-particle
AMP, which could be explained by a higher exhaled fraction or the
discrepancy between deposition in the peripheral airways and an out-
come measure of the more central airways (FEV1) [75]. For allergens,
signiﬁcant eﬀects of particle size on the response to cat and mite al-
lergen have been found, with larger particles (around 10 μm) being
more eﬀective in inducing the immediate response [76,77]. A study
investigating the eﬀect of particle size on responses to endotoxin found
a greater inﬂammatory response at the bronchial and systemic level
when challenged with larger particles, although it could not be
concluded whether this was due to regional distribution diﬀerences or
the higher total lung dose [78].
3.4. Patient-related factors aﬀecting aerosol deposition
Patient-related factors, such as the size and morphology of the or-
opharynx and bronchial tree, and the severity of lung disease can also
aﬀect aerosol deposition patterns [79]. Additionally, inhalation ﬂow
rate has an important inﬂuence on the site of deposition [80]. A higher
ﬂow rate shifts deposition to the higher airways at the cost of peripheral
deposition. The patient's ﬂow rate should therefore be adjusted to the
type of delivery device being used to prevent loss of aerosol through
deposition in the throat. Newer delivery systems that provide electronic
control over the inhalation ﬂow rate and volume (e.g. APS Pro system,
see section 4.1, and AKITA) can provide better control over the deliv-
ered dose and deposition in the lungs [81–83].
Current medication use of patients undergoing a bronchial chal-
lenge has to be accounted for as well, since these treatments are in-
tended to reduce or prevent the symptoms evoked during the challenge.
To prevent possible confounding eﬀects on the test outcome, lung
medications have to be withheld for a speciﬁed time prior to execution
of the test. The duration of withholding is dependent on the mechanism
of action of the drug and ranges from a few hours for short-acting beta-
agonists up to a few days for long-acting anticholinergics or even weeks
for ICS (depending on the challenge agent and the aim of the challenge
test).
4. Optimisation and standardisation of challenge delivery per
agent
Both optimisation and standardisation of challenge methods by
diﬀerent agents are urgently needed, in order to address the issues
identiﬁed in the preceding section and make scientiﬁc progress towards
more precise and rigorously controlled diagnostic procedures. Some
eﬀorts have already been undertaken in this regard, for example with
the mannitol test (Aridol/Osmohale; see section 4.2).
4.1. Methacholine
Soon after publication of the ﬁrst universal guidelines for metha-
choline challenge in 2000, which recommend both the dosimeter
method and tidal breathing method, studies began to appear that in-
vestigated the comparability of the two dosing protocols. The ﬁrst study
reported similar results (geometric mean PC20 1.8mg/mL for tidal
breathing vs. 1.6 mg/mL for dosimeter). However, the authors com-
pared diﬀerent dosing protocols (twofold vs. fourfold increases in
concentration for tidal breathing and dosimeter respectively) [84].
Cockcroft et al. addressed this disparity by comparing identical dosing
regimens (doubling concentrations) and found that the tidal breathing
method, which exposes the subject to twice as much aerosol at each
concentration, resulted in a PC20 that was 1.6 (PC20 < 1mg/mL) to
2.1-fold (PC20 > 1mg/mL) lower compared to the dosimeter method
[85]. This diﬀerence between subjects with mild and severe hyperre-
sponsiveness has been suggested to be explained by bronchodilator
and/or bronchoprotective eﬀects of the inhalation manoeuvre adopted
in the dosimeter method [85,86]. Prieto et al. reported a diﬀerence of
0.78 doubling concentrations, with dosimeter values being higher than
tidal breathing values, but found similar values for slope and level of
plateau of the dose-response curve [87]. Acknowledging the diﬀerence
in administered volume, they performed another study in which they
administered the same volume of challenge. Still an average diﬀerence
in PC20 of 0.9 doubling concentrations was reported [88]. However,
when looking at the individual subjects it can be seen that this diﬀer-
ence was mainly caused by a higher number of non-responders when
using the dosimeter method (Fig. 3). This may actually indicate that in
some subjects with (mild) asthma the bronchodilatory eﬀect of deep
A.J. Lexmond et al. Pulmonary Pharmacology & Therapeutics 49 (2018) 27–35
30
inhalations can indeed eﬀectively counteract any bronchoconstriction
induced by methacholine, as suggested by Cockcroft et al. [85]. Indeed
deep-breath methods have now been excluded from the new technical
standard on methacholine challenge for this reason [6].
More recent investigations into methacholine challenge method
optimisation focused on the delivery systems used, as the nebulisers
recommended in the ﬁrst guidelines [11] had become obsolete [89].
The Aerosol Provocation System (APS) Pro (CareFusion) is especially
noteworthy in this respect. The APS Pro system is a computer-con-
trolled nebuliser system speciﬁcally developed for bronchial challenge
testing with methacholine and can be integrated with other CareFusion
systems for spirometry, impulse oscillometry, respiratory resistance and
body plethysmography depending on the outcome measure of choice.
The dosimeter method is the preferred method, although the system can
also be used for the tidal breathing method. The PD20 from a pulse of
aerosol of a single methacholine concentration was found to correlate
well with the PC20 obtained with a standard dosimeter test [90]. In vitro
studies indicate that these new delivery systems often have a higher
output rate than the systems recommended in the ﬁrst guidelines, thus a
faster delivery of the challenge, which should be controlled for in terms
of exposure time [70,89].
The plethora of available nebuliser systems (with variable output
rates) introduces new concerns regarding equivalence of the test results
obtained with diﬀerent systems. Interestingly, it has been found that no
diﬀerences between test systems are found when the PD20 is calculated
[91,92] instead of the PC20 [91,93], which has led to the re-
commendation to use the PD20 as the end-point in the new technical
standard [6]. On a diﬀerent note, using more eﬃcient nebulisers also
introduces a risk of extreme individual responses to methacholine
aerosols. Patients who are highly responsive to methacholine may ex-
perience large drops in FEV1 when the full dose is presented to them in
a shorter time, which should be accounted for by thorough safety as-
sessment of using these more eﬃcient nebulisers.
4.2. Mannitol
Bronchial challenge with mannitol has been developed to overcome
technical diﬃculties (i.e. the need for ﬁlters and scales to determine the
administered volume) encountered with bronchial challenge tests using
hypertonic saline [20,94,95]. This agent has been shown to cause
contraction of ASM through release of inﬂammatory mediators such as
leukotriene E4 and prostaglandin D2, which are thought to be released
from mast cells [96]. BHR measured in response to inhaled mannitol is
dependent on the presence of inﬂammation and can be reduced by ICS
treatment [97,98]. The low sensitivity (59.8%) of the mannitol test
compared with the clinical assessment determined in more than 500
subjects was attributed to ICS use by 75% of the diagnosed asthmatics
in this study, as this value greatly improved when ICS-users were ex-
cluded from analysis (to 88.7%) [95]. This ﬁnding supports the concept
that mannitol responsiveness can be used to monitor ICS eﬀectiveness
[97,98] and highlights the growing appreciation that indirect challenge
tests are useful for diagnosis and monitoring treatment of current
asthma. Mannitol responsiveness – expressed as the provocative dose
that causes a 15% decrease in FEV1 (PD15) – has been found to correlate
well with responsiveness to bronchial challenge tests with other phy-
sical stimuli or AMP [99,100]. Bronchial challenge testing with man-
nitol may therefore be of particular use in diagnosis of asthma in elite
athletes, who require an oﬃcial diagnosis of asthma, but whose
bronchoconstriction is hard to induce by exercise in a laboratory setting
[101].
The mannitol challenge test is registered with various regulatory
authorities worldwide and is currently the only fully standardised
challenge method. The mannitol formulation consists of a spray-dried
powder with an MMAD of around 3.5 μm that is inhaled with a simple
capsule inhaler device. Beneﬁts of this mannitol test are that it comes in
a standardised kit that does not need any special equipment, and that it
is relatively easy to perform. However, a drawback of mannitol chal-
lenge is the deep inhalation-dependent modality of powder adminis-
tration, which has been suggested to counteract bronchoconstriction as
discussed in section 4.1. Moreover, the quantity of powder that needs to
be inhaled is large in comparison to other agents, up to a cumulative
dose of 635mg, as a consequence of its mechanism of action (i.e. in-
creasing the osmolarity of the lung lining ﬂuid). This in combination
with the low resistance device, and hence a high inspiratory ﬂow rate,
can result in cough through a mechanical cough reﬂex due to or-
opharyngeal deposition of the mannitol [102]. In a phase III study in-
vestigating the safety and eﬃcacy of inhaled mannitol as a bronchial
challenge test, cough occurred in 535 of 592 (of whom 91 were non-
asthmatic) subjects. In some cases, cough was so severe that the test had
to be delayed (one in seven subjects), or even ended prematurely (one
in 100 subjects) [95]. Although cough does not occur exclusively in
subjects with asthma, it has been demonstrated that cough in response
to inhaled mannitol is associated with asthma [103], which would be
interesting to elucidate further. To which extent the occurrence of
(severe) cough is diagnostic for asthma and to which extent it is due to
oropharyngeal deposition of mannitol could be investigated by pro-
voking subjects with the same mannitol formulation, but using a high-
resistance inhaler device and controlled slow inhalation to minimise
throat deposition.
4.3. Adenosine
Other eﬀorts towards optimisation have been undertaken with in-
haled adenosine. Adenosine and its precursor AMP have been the
subject of a considerable amount of research in respiratory medicine
since the early 1980s. Adenosine, a purine nucleoside involved in many
biological processes, is considered a pro-inﬂammatory mediator in
asthma [104] as it is thought to induce mast cell degranulation, a
process mediated through the A2b receptor, leading to contraction of
ASM and most notably airway eosinophilia [105,106]. More recently a
role for A1 receptors has been implicated in the contraction of ASM
from subjects with asthma induced by adenosine [107], suggesting that
adenosine triggers bronchoconstriction through both inﬂammatory and
neuronal pathways.
Historically, AMP has been used instead of adenosine because of its
much higher aqueous solubility, which is required for nebulisation, and
it is generally assumed that AMP is converted in vivo to adenosine in-
stantaneously by endonucleotidases when it comes in contact with lung
lining ﬂuid [10]. However, because of the above mentioned eﬀects of
high AMP concentrations on aerosol particle size produced by neb-
ulisation [70], an adenosine dry powder challenge test has been de-
veloped that consists of simple spray-dried formulations containing
pure adenosine or adenosine diluted with lactose, which so far have
Fig. 3. Comparison of tidal breathing and dosimeter methacholine PC20 in 27 subjects
with suspected asthma. The dashed lines indicate seven subjects in whom no dosimeter
PC20 was obtained. Reproduced with permission from Ref. [82].
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only been administered with an investigational inhaler device. With
this inhaler, the entire dose range of adenosine (0.04–80mg) was
consistently delivered in the ﬁrst proof-of-concept studies that have
been performed with this formulation [108–110]. So far, these studies
justify the chosen dose range for adenosine and indicate that the re-
sponse rate and thus diagnosis of asthma can be improved by the ad-
ministration of the higher doses that are possible with the powder
formulation. These ﬁndings now have to be complemented by studies in
healthy subjects and in subjects with lung diseases other than asthma to
determine the speciﬁcity and sensitivity of this test. Since the test
concerns a powder for inhalation, any eﬀects on bronchoconstriction of
the deep-inhalation dependent administration should also be con-
sidered for this adenosine challenge test.
4.4. Occupational agents and allergens
For occupational agents, the suspected causative agent should be
delivered in the same conditions that it is found in the workplace in
terms of physical and chemical properties in relevant concentrations
[38]. It is now recognised that there are a large variety of occupational
agents and allergens and therefore a handbook has recently been pre-
pared that summarises the delivery methods for the most commonly
used agents (see online supplement to [38]). This handbook provides an
excellent start towards harmonisation of speciﬁc inhaled challenges,
although it could beneﬁt from inclusion of recommendations on
nebulisers for those agents that are administered following a tidal
breathing or dosimeter method.
Allergens are administered in very low doses compared to the
nonspeciﬁc bronchial challenges. Nebulisation can therefore in general
be considered a suitable administration method, provided the stability
of the agent is checked during storage and upon administration, par-
ticularly for more complex molecules (e.g. antigens). Chemical stability
issues upon storage arise when an agent is sensitive to degradation
reactions (e.g. oxidation, hydrolysis), as these occur faster in aqueous
conditions than in the dry state. Additionally, stability can become an
issue when the stresses induced by the nebulisation process itself may
damage the material(s) (e.g. proteins) in the formulation [111,112].
4.5. LPS
LPS is very stable and can withstand high temperatures and strong
shear forces. It can be kept in solution for up to a month. However, LPS
adheres readily and strongly to surfaces such as glass, for example to
the vial in which it is stored. Extra care (e.g. rigorous vortexing) should
therefore be taken in the preparation of the nebuliser solution.
Additionally, endotoxins from diﬀerent sources can have a diﬀerent
biological activity (potency). Studies report the use of diﬀerent sources
of LPS and diﬀerent doses, ranging from 0.5 to 100 μg [5,52–54,59–62].
However, expressing dose in units of weight has little value because of
the diﬀerent potencies. Variability in the dose delivered to patients is
further increased by diﬀerences in administration method. Both dosi-
meter and tidal breathing methods have been used to date and the
diﬀerences between devices and inhalation manoeuvres inevitably re-
sult in diﬀerences in the delivered and deposited doses.
The lack of control of dose in terms of potency, in addition to dif-
ferences in administration methods, complicates the comparison of
studies performed over a period of about 30 years. Studies have been
performed in healthy [5,51–54,58–62,113] and diseased subjects
[55,56,114,115], in smokers [116] and non-smokers, but the potency of
the LPS was often not reported. Although a promising disease model,
standardisation of the dosing protocol and administration method
should be established before LPS challenge can be accepted as a vali-
dated tool to be used more widely in drug development studies. Other
issues that need to be addressed are the lack of dose-response studies
performed in humans and uncertainty regarding why some people do
not respond to LPS inhalation. To study the latter issues, it is imperative
to know the exact dose of LPS that is delivered and its potency. The ﬁrst
steps forward should be to decide on a preferred administration method
(i.e. slow deep inhalation) and performing a potency measurement of
the LPS in the nebuliser solution to be used for administration.
5. Conclusions
Inhaled airway challenges are versatile tests that are relatively easy
and cheap to perform. Classical bronchial challenge tests that assess
BHR have proven their value in excluding or conﬁrming a suspected
diagnosis of asthma and have been shown to be useful for monitoring
the disease and eﬀectiveness of therapy. These tests can thus help in
providing more accurate information to patient and prescriber as to
how to treat an individual patient. As such, bronchial challenge tests
can help in improving the individual patient's health through better
treatment of their disease. In research and development, inhaled airway
challenge can be applied even more widely, from studying disease
mechanisms to investigating the eﬀectiveness of new drugs. Careful
selection of the challenge agent may provide signiﬁcant beneﬁts, in
terms of both selecting suitable subjects (e.g. using response to a dis-
criminatory challenge as an inclusion criterion) and addressing the
research question. There is also a lot to be gained through optimisation
and reporting of challenge test posology, especially to ensure the
comparability of studies performed by diﬀerent laboratories. In general
all compounds described so far would strongly beneﬁt from the de-
velopment of deﬁned inhalation systems that provide a reproducible
and reliable deposition in the lungs and further standardisation of ad-
ministration protocols as has been done for mannitol (Table 1). Im-
proved delivery may also open doors for revisiting some challenge
agents that have been used in the past, but were abandoned due to lack
of reproducibility. Creating a “tool box” of well-characterised challenge
agents with tailored delivery systems would provide a valuable tool for
Table 1
Opportunities to improve the application of bronchial challenge testing.
Issue Need
Delivery method optimisation Control (and quantiﬁcation) of delivered dose by optimising the production and administration of challenge agent aerosols with suitable
aerodynamic size distributions. This will require the tailoring of delivery methods for each individual challenge agent.
Standardisation International consensus on best practice.
Inter-lab comparisons to verify the reproducibility of standard methods.
Reporting of dose characterisation/validation for all research studies.
Speciﬁc issues for mannitol Investigate the relative contributions of throat deposition and increased airway sensitivity to the occurrence of cough in asthma.
Speciﬁc issues for adenosine Compare responsiveness to dry powder adenosine challenge to responsiveness to nebulised AMP including the response of healthy subjects and
patients with lung diseases other than asthma.
Determination of the speciﬁcity and sensitivity of dry powder adenosine bronchial challenge in patients with asthma.
Speciﬁc issues for allergens Extension of existing guidelines [37] to include recommendations on nebulisers for those agents that are administered following a tidal breathing
or dosimeter method.
Veriﬁcation of chemical stability and tolerance to nebulisation on a case-by-case basis.
Speciﬁc issues for LPS Control of test agent potency and reproducibility of delivery (dose and lung distribution).
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studying and discriminating diﬀerent airway diseases, but also for in-
vestigating mechanisms and novel treatments for aﬀecting BHR.
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